Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LCAR-B38M CAR-T in relapsed/refractory multiple myeloma
NCT03758417Phase 2Terminated
- Sponsor
- Legend Biotech Corporation
- Start
- Jan 2019
- Primary completion
- Jul 2025
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ciltacabtagene autoleucel in multiple myeloma (MM), sponsored by Legend Biotech Corporation. Primary endpoint: Overall Response Rate. Started Jan 2019; status: terminated.
02
Drugs
ciltacabtagene autoleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03758417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03758417.